Biogen Pharmachem Industries Limited
Key Financial Figures
- Total Income: ₹255.80 lakh (comprising other income only)
- Net Expenses: ₹160.13 lakh
- Employee Benefit Expense: ₹28.28 lakh
- Other Expenses: ₹131.85 lakh (including annual custody fees ₹36.13 lakh, balance written off ₹63.84 lakh, stamp duty ₹12.96 lakh)
- Profit Before Tax: ₹95.67 lakh
- Tax Expense: ₹9.73 lakh (current tax)
- Net Profit for the Year: ₹85.95 lakh
- Earnings Per Share (Basic & Diluted): ₹0.01
Capital Structure Impact
- Authorized Capital: ₹9,100.00 lakh (91,00,00,000 equity shares of ₹1 each)
- Issued, Subscribed & Paid-up Capital: Increased from ₹6,526.03 lakh (65,26,03,000 shares) to ₹9,026.03 lakh (90,26,03,000 shares)
- Increase Due To: Allotment of 25,00,00,000 equity shares on conversion of fully convertible warrants issued on preferential basis to non-promoter group on 15.04.2025
- Security Premium: ₹1,700.00 lakh (previous year: nil)
- Money Received Against Share Warrants: ₹3,570.00 lakh (previous year), fully converted during current year
Significant Balances (as at 31.03.2026)
- Investments: ₹3,278.23 lakh (including quoted equity shares ₹2,372.71 lakh, unquoted equity shares ₹34.00 lakh, partnership firm investment ₹871.51 lakh)
- Loans Given: ₹6,612.97 lakh (unsecured, considered good)
- Cash & Cash Equivalents: ₹32.16 lakh
- Other Financial Assets: ₹16.53 lakh (TDS receivable)
- Other Current Liabilities: ₹31.18 lakh (including tax provision ₹9.73 lakh)
Corporate Governance & Board Details
Board of Directors:
- Chandrakant Govindbhai Parmar (Director)
- Kelash Bunkar (Whole-time Director & CFO)
- Chhayaben Parmar (Director)
- Narendrakumar Vaniya (Director)
- Aman Patel (Director)
- Harshadkumar Rathod (Director)
Key Managerial Personnel:
- Kelash Bunkar (Whole-time Director & CFO)
- Khushboo Khandelwal (Company Secretary)
Auditor: M/s. Goenka Mehta & Associates, Chartered Accountants, Rajkot (Firm Registration No: 129445W)
Share Transfer Agent: M/s Satellite Corporate Services Private Limited, Mumbai
AGM Details
- Date: Tuesday, 29th September 2026 at 04:00 PM
- Mode: Video Conferencing/Other Audio Visual Means
- Business:
1. Adoption of audited financial statements
2. Re-appointment of Mr. Kelash Bunkar (DIN: 10911360) who retires by rotation
3. Re-appointment of statutory auditors M/s. Goenka Mehta & Associates for 5 years
Regulatory Compliance Matters
- Secretarial Audit Qualifications:
- Non-compliance with certain SEBI LODR regulations regarding publication of notices and quarterly results
- Non-appointment of Internal Auditor as required under Section 138 of Companies Act, 2013
- Income Tax Dispute: ₹303.10 lakh pending with ITAT
- Book Closure: 22nd September 2026 to 29th September 2026 (both days inclusive)
Operational Review
- Company engaged in trading of shares and securities
- No significant business activities due to scarcity of working capital funds
- No manufacturing activities conducted
- No subsidiaries, joint ventures or associate companies
- No deposits accepted within meaning of Section 73 of Companies Act, 2013
Other Disclosures
- No dividend recommended for the year
- No amount transferred to reserves
- No material related party transactions
- No material changes affecting financial position post year-end
- No significant orders passed by regulators/courts impacting going concern
- No fraud reported by auditors
- No sexual harassment complaints received
- Pending income tax dispute of ₹303.10 lakh with ITAT
Cash Flow Implications
- Net Cash from Operating Activities: ₹156.83 lakh
- Net Cash used in Investing Activities: ₹956.29 lakh (mainly investments ₹893.82 lakh, increase in loans ₹62.47 lakh)
- Net Cash from Financing Activities: ₹630.00 lakh (from preferential warrants)
- Net Decrease in Cash: ₹169.46 lakh